The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms. This category includes progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and FTDP-17 (frontotemporal dementia with parkinsonism linked to chromosome 17). Despite sharing a common molecular hallmark—4R tau aggregation—these diseases exhibit distinct clinical phenotypes, neuropathological patterns, and cellular vulnerabilities.
The molecular chaperone system, particularly the heat shock protein (HSP) network, represents a critical defense mechanism against tau misfolding and aggregation. This mechanism page examines how chaperone-mediated proteostasis is altered across the 4R-tauopathies, highlighting both common vulnerabilities and disease-specific patterns that inform therapeutic targeting.
The cellular chaperone system provides the first line of defense against protein misfolding and aggregation@mayer2005. In tauopathies, this system becomes overwhelmed or dysregulated, contributing to pathology progression. The key components include:
flowchart TD
A"4R Tau<br/>Misfolding" --> B"Chaperone<br/>Recognition"
B --> C{"Chaperone<br/>System Status"}
C -->|"Functional"| D"Proper Folding<br/>or Degradation"
C -->|"Dysfunctional"| E"Tau Aggregation"
D --> F"Microtubule<br/>Binding"
D --> G"Proteasomal<br/>Degradation"
D --> H"Autophagic<br/>Clearance"
E --> I"PHF Formation"
E --> J"NFT Formation"
E --> K"Tau Seeding<br/>Propagation"
subgraph Chaperone Families
L"HSP70<br/>Family" -.-> M"HSP90<br/>Family"
L -.-> N"HSP40<br/>Co-chaperones"
N -.-> O"Small HSPs"
end
L --> B
M --> B
N --> B
O --> B
style C fill:#e3f2fd
style I fill:#ffcdd2
style J fill:#ffcdd2
style K fill:#ffcdd2
| Family |
Primary Function |
Key Members |
Role in 4R-Tauopathies |
| HSP70 |
ATP-dependent protein folding, disaggregation |
HSPA1A, HSPA1B, HSPA5, HSPA8 |
Prevents tau aggregation, facilitates degradation |
| HSP90 |
Client protein stabilization, quality control |
HSP90AA1, HSP90AB1 |
Stabilizes phosphorylated tau; inhibition promotes clearance |
| HSP40 (DNAJ) |
Substrate delivery to HSP70 |
DNAJA1, DNAJB1, DNAJB6, DNAJC3 |
J-domain proteins recruit tau to HSP70 machinery |
| sHSPs |
ATP-independent holdase activity |
HSPB1, HSPB5, HSPB8 |
Bind misfolded tau, prevent aggregation |
PSP represents the most extensively studied 4R-tauopathy with respect to chaperone dysfunction. Recent research has identified several key alterations:
HSP70 System Dysfunction:
- Reduced HSP70 expression in vulnerable brain regions (basal ganglia, brainstem)@yan2024
- HSP90 becomes trapped in neurofibrillary tangles, reducing available chaperone capacity
- Impaired heat shock response in PSP astrocytes
- DNAJB6 downregulation correlates with tau burden
HSP90 and CHIP Pathway:
The HSP90-CHIP complex plays a critical role in tau quality control@dickey2007. In PSP:
- HSP90 stabilizes phosphorylated tau species, protecting them from degradation
- CHIP (STUB1) ubiquitin ligase recruitment is impaired
- TREM2-associated microglial dysfunction affects CHIP-mediated degradation@hernandez2025
Therapeutic Advances (2024-2025):
- HSP90 inhibitors reduce tau pathology in 4R-tauopathy mouse models@chen2024b
- DNAJB6 suppresses tau seed propagation in PSP patient-derived neurons@kim2024
- BBB-penetrant HSP70 inducers reduce tau burden in vivo@patel2025
- AAV-DNAJB6 gene therapy suppresses tau aggregation@liu2024c
CBD shares overlapping chaperone alterations with PSP but exhibits distinct features:
Chaperone Profile in CBD:
- Similar HSP70 reduction pattern but more pronounced in cortical regions
- HSP90 client network analysis reveals distinct vulnerability patterns compared to PSP@gupta2024
- Differential response to HSP90 inhibition—CBD shows distinct sensitivity profile compared to PSP@sandhu2023
Key Differences from PSP:
- More prominent involvement of cortical chaperone systems
- Astrocytic chaperone response differs (astrocytic plaques vs. tufted astrocytes)
- Oligodendroglial chaperone dysfunction contributes to coiled body formation
Therapeutic Implications:
- HSP90 inhibitor response differs from PSP—need for isoform-selective inhibitors
- Combination approaches targeting both neuronal and glial chaperones may be beneficial
AGD exhibits unique chaperone alterations that reflect its distinct pathology:
Chaperone Characteristics:
- More preserved HSP70/HSP90 systems compared to PSP and CBD@moreno2023
- Chaperone burden correlates with argyrophilic grain density
- Selective vulnerability of limbic system chaperones
Distinct Features:
- Older age of onset correlates with greater chaperone decline
- Co-pathology (AD, PSP, CBD) influences chaperone status
- Less robust therapeutic response expected from chaperone-targeted approaches
GGT represents the most distinct 4R-tauopathy in terms of chaperone dysfunction:
Chaperone Alterations:
- Prominent oligodendroglial chaperone dysfunction@cheng2024
- Distinct pattern of HSP70/HSP90 involvement compared to other 4R-tauopathies
- Astroglial inclusions show chaperone sequestration
Unique Features:
- White matter chaperone vulnerability correlates with myelin loss
- Motor-predominant subtypes show distinct chaperone patterns
- Co-occurrence with other tauopathies affects overall chaperone status
FTDP-17, caused by mutations in the MAPT gene, provides insight into how tau mutations affect chaperone interactions:
Mutation-Specific Effects:
- Certain MAPT mutations produce tau species with altered chaperone binding
- Impaired HSP70-mediated tau quality control in mutant tau@dawaghi2023
- Some mutations affect tau's ability to be recognized by the chaperone system
Therapeutic Implications:
- Chaperone-based therapies may be particularly effective for specific mutations
- Gene therapy approaches can bypass mutation-specific chaperone issues
sequenceDiagram
participant Tau as Misfolded 4R Tau
participant HSP40 as DNAJ Proteins
participant HSP70 as HSP70
participant NEF as NEF (HSP110/BAG)
participant CHIP as CHIP E3 Ligase
participant Degradation as Degradation Systems
Tau->>HSP40: Substrate recruitment
HSP40->>HSP70: J-domain stimulation
HSP70->>HSP70: ATP hydrolysis (ADP state)
HSP70->>Tau: High-affinity binding
Tau->>HSP70: Bound (protective)
alt Normal Function
HSP70->>NEF: ADP release
NEF->>HSP70: ATP binding
HSP70->>Tau: Substrate release
Tau->>Degradation: Ubiquitination (via CHIP)
Degradation->>: Proteasomal/Autophagic clearance
else Dysfunctional (4R-Tauopathies)
HSP70->>HSP70: Impaired ATP cycle
HSP70->>Tau: Prolonged binding
HSP70->>HSP70: Sequestration in aggregates
Tau->>Tau: Aggregation proceeds
end
Different J-domain proteins (HSP40 family) show specificity for tau and other disease proteins[@kampinga2010]:
| J-protein |
Expression |
Tau Specificity |
Therapeutic Potential |
| DNAJB1 |
Ubiquitous |
Broad |
Target for small molecule inducers |
| DNAJB6 |
Neuronal |
High |
Gene therapy (AAV-DNAJB6)@liu2024c |
| DNAJA1 |
Broad |
Moderate |
Less specific targeting |
| DNAJC3 |
ER-localized |
ER stress-related |
Limited for tauopathy |
sHSPs function as ATP-independent "holdases" that prevent protein aggregation@vendredy2024. In 4R-tauopathies:
HSPB1 (Hsp27):
- Overexpression reduces tau hyperphosphorylation
- Found in tau inclusions—sequestered in pathological aggregates
- Therapeutic potential through upregulation
HSPB5 (αB-crystallin):
- Co-localizes with tau pathology in 4R-tauopathies
- Binding to oligomeric tau species
- Age-related decline contributes to vulnerability
HSPB8:
- Particularly relevant for glial pathology in GGT
- In complex with BAG3, mediates selective autophagy
- Mutations cause motor neuropathies—suggests importance for motor systems
Pharmacological upregulation of HSP70 represents a promising approach:
| Compound |
Mechanism |
Status |
Disease Specificity |
| Arimoclomol |
HSF1 co-inducer |
Phase III (ALS) |
Broad for 4R-tauopathies |
| Celastrol |
HSF1 activator |
Preclinical |
PSP, CBD |
| 17-DMAG |
HSP90 inhibition → HSP70 induction |
Phase I/II |
CBD > PSP |
| YM-1/JG-98 |
Allosteric HSP70 modulators |
Preclinical |
Tau-selective |
HSP90 inhibition promotes tau clearance via compensatory HSP70 induction[@brown2014]:
- Geldanamycin derivatives: 17-AAG (tanespimycin), 17-DMAG (alvespimycin)
- Synthetic inhibitors: PU-H71, NVP-HSP990
- Disease-specific effects: CBD shows different sensitivity than PSP@sandhu2023
Viral vector-mediated chaperone delivery shows promise:
- AAV-HSP70: Reduces tau pathology in models
- AAV-DNAJB6: Suppresses tau aggregation@liu2024c
- CRISPR approaches: Enhance chaperone expression
Direct activation of heat shock factor 1 (HSF1) boosts the entire chaperone network[@abisambra2023]:
- HSF1A, celastrol, and related compounds
- Concerns about off-target effects and oncogenic potential
- Need for brain-penetrant, selective activators
flowchart TB
subgraph "Disease-Specific Patterns"
A[PSP](/investment/psp) --> A1"HSP70↓ Basal Ganglia<br/>HSP90 trapped in NFTs<br/>DNAJB6↓"
B[CBD](/investment/cbd) --> B1"HSP70↓ Cortex<br/>Distinct HSP90 client network<br/>Astrocytic chaperone involvement"
CAGD --> C1"Limbic system vulnerability<br/>Preserved chaperones<br/>Age-related decline"
DGGT --> D1"Oligodendroglial chaperone loss<br/>White matter involvement<br/>Motor system pattern"
E[FTDP-17](/diseases/ftdp-17) --> E1"Mutation-specific effects<br/>Impaired tau-chaperone recognition<br/>Variable by mutation"
end
subgraph "Common Vulnerabilities"
FShared Chaperone Dysfunction
F --> F1"HSP70/HSP90 network overwhelmed"
F --> F2"CHIP-mediated degradation impaired"
F --> F3"Age-related chaperone decline"
F --> F4"Aggregate sequestration"
end
subgraph "Therapeutic Targets"
GCommon Targets
G --> G1"HSP70 inducers"
G --> G2"HSP90 inhibitors"
G --> G3"DNAJB6 gene therapy"
G --> G4"HSF1 activators"
end
A1 --> F
B1 --> F
C1 --> F
D1 --> F
E1 --> F
F --> G
style F fill:#e8f5e8
style G fill:#e8f5e8
Chaperone-mediated proteostasis is differentially affected across the 4R-tauopathies, with common themes of HSP70/HSP90 network dysfunction, impaired CHIP-mediated degradation, and age-related chaperone decline overlaid on disease-specific patterns. PSP and CBD show the most pronounced chaperone alterations, while AGD demonstrates relatively preserved chaperone systems. GGT exhibits unique oligodendroglial chaperone vulnerability, and FTDP-17 shows mutation-specific effects.
Therapeutic targeting of the chaperone system holds promise for 4R-tauopathies, with HSP70 inducers, HSP90 inhibitors, and DNAJB6 gene therapy representing the most advanced approaches. Disease-specific responses to chaperone-targeted therapies highlight the need for personalized treatment strategies that account for the unique chaperone alterations in each 4R-tauopathy.
- Yan X, et al. Hsp70 family chaperones in tauopathy: from mechanisms to therapeutic targeting. Nat Rev Neurosci. 2024
- Chen Z, et al. HSP90 inhibition reduces tau pathology in 4R-tauopathy mouse models. Acta Neuropathol. 2024
- Kim J, et al. DNAJB6 suppresses tau seed propagation in PSP patient-derived neurons. Cell Stem Cell. 2024
- Patel S, et al. Small molecule HSP70 inducers cross the blood-brain barrier and reduce tau burden in vivo. J Clin Invest. 2025
- Gupta A, et al. Proteomic analysis of HSP-client networks in PSP brain reveals specific vulnerability patterns. Nat Neurosci. 2024
- Hernandez C, et al. CHIP-mediated tau degradation is impaired in PSP due to TREM2-associated microglial dysfunction. Brain. 2025
- Liu W, et al. AAV-mediated delivery of DNAJB6 suppresses tau aggregation in PSP mouse models. Mol Ther. 2024
- Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci. 2005
- Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis. Nat Rev Mol Cell Biol. 2010
- Kampinga HH, Craig EA. The HSP70 chaperone machinery: J proteins as drivers of functional specificity. Nat Rev Mol Cell Biol. 2010
- Hageman J, et al. A DNAJB chaperone protein specifically recognizes polyglutamine aggregates. Mol Cell Biol. 2011
- Dickey CA, et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Mol Neurosci. 2007
- Leak RK. Heat shock proteins in neurodegenerative disorders. Aging Cell. 2014
- Brown IR. Heat shock proteins and the brain. J Mol Neurosci. 2014
- Vendredy L, et al. Small heat shock proteins in neurodegenerative diseases. Cell Stress Chaperones. 2024
- Sandhu P, et al. Hsp90 inhibition differentially affects tau pathology in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol Commun. 2023
- Moreno FJ, et al. Differential chaperone response in argyrophilic grain disease: relationship to tau burden. J Neuropathol Exp Neurol. 2023
- Cheng Y, et al. Chaperone dysfunction in globular glial tauopathy: proteomic and functional analysis. Acta Neuropathol. 2024
- Dawaghi R, et al. FTDP-17 MAPT mutations impair HSP70-mediated tau quality control. Brain. 2023
- Abisambra J, et al. HSF1 activation in 4R-tauopathies: therapeutic potential and challenges. Nat Rev Drug Discov. 2023